OTCMKTS:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $0.01 +0.01 (+2,400.00%) As of 08/21/2026 10:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Lyra Therapeutics Stock (OTCMKTS:LYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$0.01▼$0.0150-Day Range$0.00▼$0.7152-Week Range$0.00▼$8.75Volume425 shsAverage Volume1,190 shsMarket Capitalization$17.70 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects. The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS). LYR-210 is currently advancing through pivotal Phase 3 clinical trials, following positive Phase 2 data demonstrating significant improvements in symptom control and quality of life measures. In addition, Lyra is developing LYR-220 for chronic obstructive pulmonary disease (COPD) and exploring other respiratory indications, all based on its sustained-release implant technology. Founded in 2015 and headquartered in Lynnfield, Massachusetts, Lyra Therapeutics operates research and development facilities in the United States. The company is led by President and Chief Executive Officer Bryan J. Bork, supported by a management team with extensive expertise in drug delivery, drug development and regulatory strategy. As Lyra advances its pipeline through clinical development, it seeks to establish partnerships for commercial manufacturing and expand its platform into additional ENT and respiratory disease areas. AI Generated. May Contain Errors. Read More Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LYRA Stock News HeadlinesLyra Therapeutics Ends Major Office Sublease AgreementApril 17, 2026 | tipranks.comLyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SECApril 17, 2026 | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)After layoffs, Lyra Therapeutics exits Watertown and Waltham leasesApril 14, 2026 | bizjournals.comTreating allergic fungal rhinosinusitis in childrenApril 8, 2026 | msn.comLyra Therapeutics Withdraws Nasdaq Appeal, Faces Imminent DelistingMarch 16, 2026 | tipranks.comLyra Therapeutics (LYRA) price target decreased by 30.43% to 16.32February 4, 2026 | msn.comLyra Therapeutics suspends further development of LYR-210January 13, 2026 | finance.yahoo.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $3.08 on January 1st, 2026. Since then, LYRA stock has decreased by 99.7% and is now trading at $0.01. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (OTCMKTS:LYRA) issued its quarterly earnings data on Wednesday, November, 12th. The company reported ($3.38) EPS for the quarter, beating the consensus estimate of ($5.98) by $2.60. The business had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.21 million. When did Lyra Therapeutics' stock split? Shares of Lyra Therapeutics reverse split on Wednesday, May 28th 2025.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings11/12/2025Today8/21/2026Next Earnings (Estimated)8/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:LYRA Previous SymbolNASDAQ:LYRA CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees50Year Founded2005Profitability EPS (Trailing Twelve Months)($19.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.92 million Net Margins-7,266.08% Pretax Margin-7,263.32% Return on EquityN/A Return on Assets-59.82% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$400 thousand Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value($6.04) per share Price / Book0.00Miscellaneous Outstanding Shares1,770,000Free Float1,717,000Market Cap$17.70 thousand OptionableNo Data Beta0.72 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:LYRA) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
